Recombinant DNA approaches to feline leukemia virus immunization.
We have utilized 2 recombinant DNA strategies for immunization against FeLV in cats: (a) modified live virus was attenuated by mutation and recombination, and (b) an immunogen, consisting of subunit envelope protein, was prepared in genetically engineered yeast. Results indicated that the genetically manipulated live virus preparations were not protective against FeLV challenge because they were either not attenuated in virulence or were not sufficiently antigenic. Immunization with yeast-synthesized FeLV envelope protein followed by the modified live virus gave protective immunity in cats under experimental conditions. Future immunization attempts will concentrate on enhancing the immunogenic potency of the yeast- synthesized FeLV envelope protein.
D000818:Animals; D002371:Cat Diseases / Q000276:immunology / Q000517:prevention & control*; D002415:Cats; D003001:Cloning, Molecular; D004262:DNA Restriction Enzymes; D004274:DNA, Recombinant; D005818:Genetic Engineering / Q000379:methods; D007116:Immunization, Passive; D007938:Leukemia / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D005256:Leukemia Virus, Feline / Q000235:genetics / Q000276:immunology*; D014613:Vaccines, Attenuated
D004274:DNA, Recombinant; D014613:Vaccines, Attenuated; D004262:DNA Restriction Enzymes